Core Viewpoint - WuXi Biologics (02269) announced the issuance of a total of 4.055 million ordinary shares on November 10, 2025, as part of the exercise of options under its pre-IPO share option plan adopted on January 5, 2016, and revised on August 10, 2016 [1] Summary by Category - Share Issuance - The company issued 4.055 million ordinary shares as part of the option exercise [1] - Historical Context - The share option plan was initially adopted on January 5, 2016, and revised on August 10, 2016 [1] - Future Implications - The exercise of options may impact the company's capital structure and shareholder equity [1]

Core Points - The company has proposed the adoption of the 2025 H-share incentive plan, with a maximum limit of 3 million H-shares to be acquired by the trustee based on current market prices and applicable laws [1] - The board has also decided to amend the pre-IPO share option plan, extending the first exercise period from 12 months to 24 months after the waiting period ends, subject to shareholder approval at an extraordinary general meeting [1]